Related Experiment Video

Updated: Sep 12, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Effects of ACE inhibitors versus calcium antagonists on left ventricular morphology and function in patients with

K Matsuzaki1, M Mukai, T Sumimoto

  • 1Hypertension Center, Kinki Central Hospital, Itami, Japan.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
|March 1, 1997
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitors and calcium (Ca) antagonists effectively lower blood pressure and left ventricular mass in hypertensive patients. However, ACE inhibitors offer superior improvements in left ventricular function compared to Ca antagonists.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Essential hypertension frequently leads to left ventricular hypertrophy (LVH).
  • Long-term antihypertensive therapy is crucial for managing hypertension and its cardiac consequences.

Purpose of the Study:

  • To compare the efficacy of ACE inhibitors versus Ca antagonists in treating LVH and improving LV function.
  • To assess the impact of these treatments on blood pressure and cardiac remodeling.

Main Methods:

  • A 6-month randomized trial involving 33 patients with essential hypertension and LVH.
  • Patients received either ACE inhibitors (ceronapril/delapril) or Ca antagonists (nifedipine/nicardipine).
  • Evaluated mean blood pressure (MBP), left ventricular mass (LVM), fractional shortening (FS), ejection time/pre-ejection period ratio (ET/PEP), and isovolumic relaxation time (IRT).

Main Results:

  • Both treatment groups showed significant and comparable reductions in MBP and LVM.
  • ACE inhibitors demonstrated significantly greater improvements in FS, ET/PEP, and IRT compared to Ca antagonists.
  • ACE inhibitors improved both systolic and diastolic left ventricular function.

Conclusions:

  • Both ACE inhibitors and Ca antagonists effectively reduce blood pressure and LVM in hypertensive patients.
  • ACE inhibitors provide superior benefits for left ventricular systolic and diastolic function compared to Ca antagonists.

More Related Videos

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...